Want to see RNAC full AI Analyst Report?
Total Valuation
Cartesian Therapeutics has a market cap or net worth of $267.46M. The enterprise value is $227.40.
Market Cap$267.46M
Enterprise Value$227.40
Share Statistics
Cartesian Therapeutics has 30,255,352 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding30,255,352
Owned by Insiders42.90%
Owned by Institutions4.10%
Financial Efficiency
Cartesian Therapeutics’s return on equity (ROE) is 1.03 and return on invested capital (ROIC) is -28.36%.
Return on Equity (ROE)1.03
Return on Assets (ROA)-0.44
Return on Invested Capital (ROIC)-28.36%
Return on Capital Employed (ROCE)-0.31
Revenue Per Employee37.29K
Profits Per Employee-1.74M
Employee Count75
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Cartesian Therapeutics is ―. Cartesian Therapeutics’s PEG ratio is -0.02.
PE Ratio―
PS Ratio66.95
PB Ratio-1.48
Price to Fair Value-1.48
Price to FCF-2.36
Price to Operating Cash Flow-3.42
PEG Ratio-0.02
Income Statement
In the last 12 months, Cartesian Therapeutics had revenue of 2.80M and earned -130.30M in profits. Earnings per share was -5.02.
Revenue2.80M
Gross Profit2.80M
Operating Income-86.70M
Pretax Income-139.50M
Net Income-130.30M
EBITDA-136.54M
Earnings Per Share (EPS)-5.02
Cash Flow
In the last 12 months, operating cash flow was -76.07M and capital expenditures -2.08M, giving a free cash flow of -78.16M billion.
Operating Cash Flow-76.07M
Free Cash Flow-78.16M
Free Cash Flow per Share-2.58
Dividends & Yields
Cartesian Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.85
52-Week Price Change-21.63%
50-Day Moving Average8.65
200-Day Moving Average7.53
Relative Strength Index (RSI)57.06
Average Volume (3m)250.94K
Important Dates
Cartesian Therapeutics upcoming earnings date is Nov 5, 2026, Before Open (Confirmed).
Last Earnings DateAug 6, 2026
Next Earnings DateNov 5, 2026
Ex-Dividend Date―
Financial Position
Cartesian Therapeutics as a current ratio of 8.65, with Debt / Equity ratio of -50.99%
Current Ratio8.65
Quick Ratio8.65
Debt to Market Cap0.02
Net Debt to EBITDA0.82
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Cartesian Therapeutics has paid -9.19M in taxes.
Income Tax-9.19M
Effective Tax Rate0.07
Enterprise Valuation
Cartesian Therapeutics EV to EBITDA ratio is -0.55, with an EV/FCF ratio of -0.94.
EV to Sales26.74
EV to EBITDA-0.55
EV to Free Cash Flow-0.94
EV to Operating Cash Flow-1.01
Balance Sheet
Cartesian Therapeutics has $147.61M in cash and marketable securities with $63.85M in debt, giving a net cash position of $83.75M billion.
Cash & Marketable Securities$147.61M
Total Debt$63.85M
Net Cash$83.75M
Net Cash Per Share$2.77
Tangible Book Value Per Share-$6.71
Margins
Gross margin is -766.42%, with operating margin of -3099.93%, and net profit margin of -4658.63%.
Gross Margin-766.42%
Operating Margin-3099.93%
Pretax Margin-4987.31%
Net Profit Margin-4658.63%
EBITDA Margin-4881.52%
EBIT Margin-4987.31%
Analyst Forecast
The average price target for Cartesian Therapeutics is $33.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$33.83
Price Target Upside329.36% Upside
Analyst ConsensusStrong Buy
Analyst Count8
Revenue Growth Forecast―
EPS Growth Forecast―